It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
We assessed the causal relation of four glycemic traits and type 2 diabetes liability with 167 metabolites using Mendelian randomization with various sensitivity analyses and a reverse Mendelian randomization analysis. We extracted instruments for fasting glucose, 2-h glucose, fasting insulin, and glycated hemoglobin from the Meta-Analyses of Glucose and Insulin-related traits Consortium (n = 200,622), and those for type 2 diabetes liability from a meta-analysis of multiple cohorts (148,726 cases, 965,732 controls) in Europeans. Outcome data were from summary statistics of 167 metabolites from the UK Biobank (n = 115,078). Fasting glucose and 2-h glucose were not associated with any metabolite. Higher glycated hemoglobin was associated with higher free cholesterol in small low-density lipoprotein. Type 2 diabetes liability and fasting insulin were inversely associated with apolipoprotein A1, total cholines, lipoprotein subfractions in high-density-lipoprotein and intermediate-density lipoproteins, and positively associated with aromatic amino acids. These findings indicate hyperglycemia-independent patterns and highlight the role of insulin in type 2 diabetes development. Further studies should evaluate these glycemic traits in type 2 diabetes diagnosis and clinical management.
A Mendelian randomization study on metabolic profiling of different glycemic traits suggests hyperglycemia-independent patterns and highlights the role of insulin in the development of type 2 diabetes.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 The University of Hong Kong, School of Public Health, Li Ka Shing Faculty of Medicine, Hong Kong SAR, China (GRID:grid.194645.b) (ISNI:0000 0001 2174 2757)
2 University of California Irvine, Department of Biological Chemistry, School of Medicine, Irvine, USA (GRID:grid.266093.8) (ISNI:0000 0001 0668 7243); University of California Irvine, Center for Epigenetics and Metabolism, Irvine, USA (GRID:grid.266093.8) (ISNI:0000 0001 0668 7243)
3 The University of Hong Kong, School of Public Health, Li Ka Shing Faculty of Medicine, Hong Kong SAR, China (GRID:grid.194645.b) (ISNI:0000 0001 2174 2757); City University of New York, School of Public Health and Health Policy, New York, USA (GRID:grid.212340.6) (ISNI:0000 0001 2298 5718)